Structural evaluation of degradation products of Loteprednol using LC-MS/MS: Development of an HPLC method for analyzing process-related impurities of Loteprednol
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The current investigation entails the characterization of five degradation products (DPs) formed under different stress conditions of loteprednol using liquid chromatography–tandem mass spectrometry (LC-MS/ MS). In addition, this study developed a stable high-performance liquid chromatography (HPLC) method for evaluating loteprednol along with impurities. The method conditions were meticulously fine-tuned which involved the exploration of the appropriate solvent, pH, flow of the mobile phase, columns, and wavelength. The method conditions were carefully chosen to successfully resolve the impurities of loteprednol and were employed in subsequent validation procedures. The stability profile of loteprednol was exposed to stress degradation experiments conducted under five conditions, and DPs were structurally characterized by employing LC-MS/MS. The chromatographic resolution of loteprednol and its impurities along with DPs was effectively achieved using a Phenomenex Luna 250 mm C18 column using 0.1 % phosphoric acid, methanol, and acetonitrile in 45:25:30 (v/v) pumped isocratically at 0.8 mL/min with 243 nm wavelength. The method produces an accurate fit calibration curve in 50-300 μg/mL for loteprednol and LOQ (0.05 μg/mL) – 0.30 μg/mL for its impurities with acceptable precision, accuracy, and recovery. The stress-induced degradation study revealed the degradation of loteprednol under basic, acidic, and photolytic conditions, resulting in the formation of seven distinct DPs. The efficacy of this method was validated through LCMS/ MS, which allowed for the verification of the chemical structures of the newly generated DPs of loteprednol. This method was appropriate for assessing the impurities of loteprednol and can also be appropriate for structural and quantitative assessment of its degradation products.
Abstract
The current investigation entails the characterization of five degradation products (DPs) formed under different stress conditions of loteprednol using liquid chromatography–tandem mass spectrometry (LC-MS/ MS). In addition, this study developed a stable high-performance liquid chromatography (HPLC) method for evaluating loteprednol along with impurities. The method conditions were meticulously fine-tuned which involved the exploration of the appropriate solvent, pH, flow of the mobile phase, columns, and wavelength. The method conditions were carefully chosen to successfully resolve the impurities of loteprednol and were employed in subsequent validation procedures. The stability profile of loteprednol was exposed to stress degradation experiments conducted under five conditions, and DPs were structurally characterized by employing LC-MS/MS. The chromatographic resolution of loteprednol and its impurities along with DPs was effectively achieved using a Phenomenex Luna 250 mm C18 column using 0.1 % phosphoric acid, methanol, and acetonitrile in 45:25:30 (v/v) pumped isocratically at 0.8 mL/min with 243 nm wavelength. The method produces an accurate fit calibration curve in 50-300 μg/mL for loteprednol and LOQ (0.05 μg/mL) – 0.30 μg/mL for its impurities with acceptable precision, accuracy, and recovery. The stress-induced degradation study revealed the degradation of loteprednol under basic, acidic, and photolytic conditions, resulting in the formation of seven distinct DPs. The efficacy of this method was validated through LCMS/ MS, which allowed for the verification of the chemical structures of the newly generated DPs of loteprednol. This method was appropriate for assessing the impurities of loteprednol and can also be appropriate for structural and quantitative assessment of its degradation products.
참고문헌 (28)
- S. Gorog, , TrAC Trends. Anal. Chem, 25(8), pp.755~757 (2006)[DOI]
- S. Gorog, , TrAC Trends. Anal. Chem, 101, pp.2~16 (2018)[DOI]
- D. Matmour, , Ann. Pharm. Fr, 80(3), pp.261~272 (2022)[DOI]
- "Population and Hospital Reform. Withdrawal of batches of pharmaceutical specialties made from Valsartan" (2018)[URL]
- R. V. Bhupatiraju, , J. Chem. Metrol, 17(2), pp.181~198 (2023)[DOI]
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)., "Impurities in new drug substances (Q3A)", 1~15 (2008)
- "United States Pharmacopeial Convention, Organic impurities in drug substances and drug products, United States Pharmacopeia and National Formulary (USPNF)", pp.1270~12765 (2015), Deutscher Apotheker Verlag
- S. Patel, , Res. J. Pharm. Dosage. Form. Tech, 8(1), pp.31~36 (2016)[DOI]
- R. D. Kiran, , J. Chil. Chem. Soc, 62(2), pp.3543~3557 (2017)[DOI]
- P. Druzgala, , J. Steroid. Biochem. Mol. Biol, 38(2), pp.149~154 (1991)[DOI]
- J. D. Sheppard, , Adv. Ther., 33(4), pp.532~552 (2016)[DOI]
- S. I. Yasueda, , J. Pharm. Biomed. Anal, 36(2), pp.309~316 (2004)[DOI]
- Y. K. Han, , J. Chromatogr. Sci, 53(5), pp.761~766 (2015)[DOI]
- A. S. Vashi, , Indian. J. Pharm. Sci. Res, 5(4), pp.280~ (2015)
- P. M. K. Raju, , Ann. Pharm. Fr, 80(6), pp.837~852 (2022)[DOI]
- A. B. Patel, , Asian J. Res. Chem, 6(4), pp.393~397 (2013)
- K. B. Premakumari, , IOSR J. Pharm. Boil. Sci, 11(4), pp.82~ (2016)[DOI]
- R. Solanki, , Nirma. Univ. J. Pharm. Sci, 5(1), pp.27~ (2018)
- International Conference of Harmonisation. ICH, "Q1B, Stability testing : photostability testing of new drug substances and products", International Conference on Harmonization (1996)
- International Conference of Harmonisation. ICH, "Q2(R1), Validation of analytical procedures : text and methodology", International Conference on Harmonization (1994)
- U. R. Mallu, , Turk. J. Pharm. Sci, 16, pp.457~465 (2019)[DOI]
- B. K. Bikshal, , Indian. Drugs, 55, pp.41~49 (2018)[DOI]
- K. S. Girija, , Int. J. App. Pharm, 13, pp.165~172 (2021)[DOI]
- B. K. Bikshal, , Thai. J. Pharm. Sci, 42, pp.27~36 (2018)[DOI]
- R. B. Varma, , Res. J. Pharm. Technol, 15, pp.5158~5163 (2022)[DOI]
- B. H. R. Varma, , Res. J. Chem. Environ, 27, pp.54~61 (2023)[DOI]
- V. B. Rajesh, , Rasayan. J. Chem, 15, pp.2373~2381 (2022)[DOI]
- V. B. Rajesh, , Ann. Pharm. Fr, 81, pp.64~73 (2013)[DOI]